Please assess the completion status of the following clinical trial:

Trial Title: A Study of TAS-120 in Patients With Advanced Solid Tumors

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 23.0

Eligibility Criteria:
Inclusion Criteria:~1. Provide written informed consent~2. Age ≥ 18 years of age~3. Has histologically or cytologically confirmed, locally advanced or metastatic cancer~4. The following specific criteria for each study portion~   Phase 1 (Dose Escalation):~  * Patients with any type of solid tumor~  * Disease progression following standard therapies or intolerant to prior standard therapies~   Phase 1 (Dose Expansion)~  * Have at least one FGF/FGFR aberration~  * Disease progression following standard therapies or were intolerant to prior standard therapies (including prior FGFR inhibitors).~  * Have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) guidelines (version 1.1, 2009) for advanced solid tumors or Response Assessment in Neuro-Oncology criteria (2010) for brain tumors.~  * Patients with any of the following tumor types~     * Patients with intrahepatic or extrahepatic CCA harboring FGFR2 gene fusions or other FGFR2 aberrations~    * Patients with primary CNS tumors~    * Patients with advanced urothelial carcinoma with FGFR3 fusions or FGFR3 activating mutations~    * Patients with breast cancer or gastric cancer~    * Patients with other solid tumor types harboring FGFR gene fusions or activating mutations~    * Patients with solid tumor types and other FGF/FGFR alterations not listed above~   Phase 2~  * Patients with iCCA and FGFR2 gene rearrangements (incl fusions)~  * Have been treated with at least one prior systemic gemcitabine and platinum-based chemotherapy~  * Must have documentation of radiographic progression of disease~  * No prior FGFR inhibitor~  * Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) guidelines (version 1.1, 2009)~5. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1~6. Adequate organ function.~Exclusion Criteria:~1. History and/or current evidence of clinically significant non-tumor related alteration of calcium-phosphorus homeostasis.~2. History and/or current evidence of clinically significant ectopic mineralization/calcification.~3. History and/or current evidence of clinically significant retinal disorder~4. A serious illness or medical condition(s)~5. Pregnant or breast-feeding female

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phase 1: Dose Escalation: QOD Dosing: 8 mg (Type: EXPERIMENTAL): Participants with or without fibroblast growth factor \[FGF\]/fibroblast growth factor receptor \[FGFR\] gene abnormalities received orally TAS-120 8 milligrams (mg) orally every other day (QOD; Monday, Wednesday and Friday of each week) in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
- Phase 1: Dose Escalation: QOD Dosing: 16 mg (Type: EXPERIMENTAL): Participants with or without FGF/FGFR gene abnormalities received orally TAS-120 16 mg orally QOD (Monday, Wednesday and Friday of each week) in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
- Phase 1: Dose Escalation: QOD Dosing: 24 mg (Type: EXPERIMENTAL): Participants with or without FGF/FGFR gene abnormalities received orally TAS-120 24 mg orally QOD (Monday, Wednesday and Friday of each week) in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
- Phase 1: Dose Escalation: QOD Dosing: 36 mg (Type: EXPERIMENTAL): Participants with or without FGF/FGFR gene abnormalities received orally TAS-120 36 mg orally QOD (Monday, Wednesday and Friday of each week) in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
- Phase 1: Dose Escalation: QOD Dosing: 56 mg (Type: EXPERIMENTAL): Participants with FGF/FGFR gene abnormalities received orally TAS-120 56 mg orally QOD (Monday, Wednesday and Friday of each week) in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
- Phase 1: Dose Escalation: QOD Dosing: 80 mg (Type: EXPERIMENTAL): Participants with FGF/FGFR gene abnormalities received orally TAS-120 80 mg orally QOD (Monday, Wednesday and Friday of each week) in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
- Phase 1: Dose Escalation: QOD Dosing: 120 mg (Type: EXPERIMENTAL): Participants with FGF/FGFR gene abnormalities received orally TAS-120 120 mg orally QOD (Monday, Wednesday and Friday of each week) in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
- Phase 1: Dose Escalation: QOD Dosing: 160 mg (Type: EXPERIMENTAL): Participants with FGF/FGFR gene abnormalities received orally TAS-120 160 mg orally QOD (Monday, Wednesday and Friday of each week) in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
- Phase 1: Dose Escalation: QOD Dosing: 200 mg (Type: EXPERIMENTAL): Participants with FGF/FGFR gene abnormalities received orally TAS-120 200 mg orally QOD (Monday, Wednesday and Friday of each week) in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
- Phase 1: Dose Escalation: QD Dosing: 4 mg (Type: EXPERIMENTAL): Participants with or without FGF/FGFR gene abnormalities received a dose between 4 mg orally once daily (QD) in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
- Phase 1: Dose Escalation: QD Dosing: 8 mg (Type: EXPERIMENTAL): Participants with or without FGF/FGFR gene abnormalities received a dose between 8 mg orally QD in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
- Phase 1: Dose Escalation: QD Dosing: 16 mg (Type: EXPERIMENTAL): Participants with or without FGF/FGFR gene abnormalities received a dose between 16 mg orally QD in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
- Phase 1: Dose Escalation: QD Dosing: 20 mg (Type: EXPERIMENTAL): Participants with or without FGF/FGFR gene abnormalities received a dose between 20 mg orally QD in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
- Phase 1: Dose Escalation: QD Dosing: 24 mg (Type: EXPERIMENTAL): Participants with or without FGF/FGFR gene abnormalities received a dose between 24 mg orally QD in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
- Phase 1: Dose Expansion Cohort 1 (Type: EXPERIMENTAL): Participants with intra-hepatic or extrahepatic cholangiocarcinoma (iCCA or eCCA) harboring FGFR2 gene fusions or rearrangements and who were treated or not treated with prior FGFR inhibitors received TAS-120 20 mg tablets orally QD in each of 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
- Phase 1: Dose Expansion: Cohort 2 (Type: EXPERIMENTAL): Participants with primary central nervous system (CNS) tumors harboring FGFR gene fusions or FGFR1 activating mutations received TAS-120 20 mg tablets orally QD in each of 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
- Phase 1: Dose Expansion: Cohort 3 (Type: EXPERIMENTAL): Participants with advanced urothelial carcinoma harboring FGFR3 gene fusions or FGFR3 activating mutations received TAS-120 20 mg tablets orally QD in each of 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
- Phase 1: Dose Expansion: Cohort 4 (Type: EXPERIMENTAL): Participants with breast or gastric cancer with harboring FGFR2 amplification received TAS-120 20 mg tablets orally QD in each of 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
- Phase 1:Dose Expansion: Cohort 5 (Type: EXPERIMENTAL): Participants with tumor types harboring FGFR gene fusions or activating mutations received TAS-120 20 mg tablets orally QD in each of 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
- Phase 1: Dose Expansion: Cohort 6 (Type: EXPERIMENTAL): Participants who were not included in Cohorts 1 to 5 received TAS-120 20 mg tablets orally QD in each of 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
- Phase 1: Dose Expansion: Sub-cohort 1 (Type: EXPERIMENTAL): Participants with iCCA who were enrolled prior to the confirmation of the recommended Phase 2 dose (RP2D) received TAS-120 16 mg tablets orally QD in each of 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
- Phase 1: Dose Expansion: Sub-cohort 2 (Type: EXPERIMENTAL): Participants with other tumor types who were enrolled prior to the confirmation of the RP2D received TAS-120 16 mg tablets orally QD in each of 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.
- Phase 2 (Type: EXPERIMENTAL): Participants with iCCA with tumors harboring FGFR2 gene rearrangements received TAS-120 20 mg tablets orally QD in each of 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete